The NICE British National Formulary (BNF) and British National Formulary for Children (BNFc) sites are only available to users in the UK, Crown Dependencies and British Overseas Territories. If you believe you are seeing this page in error please contact us. Summary Description and Clinical Pharmacology Indications and Dosage Warnings and Precautions Side Effects and Adverse Reactions Drug Interactions, Overdosage, Contraindications, Other Rx Info Active Ingredients User Ratings / Reviews Side Effect Reports Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION). The dosage of metoprolol tartrate tablets should be individualized. Clomid side effects on men Xanax hiccups Cialis replacement Buy viagra online united kingdom Tablets Metoprolol have a round shape, biconvex surface, depending on the dosage they can have pinkish 50 mg or light yellow 100 mg color. The main active substance of the drug is metoprolol tartrate, its content in one tablet is 50 or 100 mg. It also includes auxiliary components Titanium dioxide. Talc. Hypromellose. Polysorbate 80. Metoprolol Succinate official prescribing information for healthcare professionals. Includes indications, dosage, adverse reactions, pharmacology and more. Switching patients taking metoprolol succinate to alternate therapy. Indications. Metoprolol tartrate is FDA-approved for hypertension, angina, and post-MI.1. Ischemic Heart Disease: Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered metoprolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, metoprolol administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol therapy abruptly even in patients treated only for hypertension. Metoprolol tartrate, USP is a selective beta1-adrenoreceptor blocking agent, available as 25, 50 and 100 mg tablets for oral administration. Metoprolol tartrate is (±)-1-(isopropylamino)-3-[p-(2-methoxyethyl) phenoxy]-2-propanol (2:1) dextro-tartrate salt, and its structural formula is: Metoprolol tartare, USP is a white, practically odorless, crystalline powder with a molecular weight of 684.82. Metoprolol is a cardioselective β1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. It may also be used for supraventricular and tachyarrhythmias and prophylaxis for migraine headaches. Metoprolol is structurally similar to bisoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The β1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At low doses, metoprolol selectively blocks cardiac β1-adrenergic receptors with little activity against β2-adrenergic receptors of the lungs and vascular smooth muscle. Unlike propranolol and pindolol, metoprolol does not exhibit membrane-stabilizing or intrinsic sympathomimetic activity. Membrane-stabilizing effects are only observed at doses much higher than those needed for β-adrenergic blocking activity. Metoprolol possesses a single chiral centre and is administered as a racemic mixture. Indications for metoprolol METOPROLOL TARTRATE Drug BNF content published by NICE, Metoprolol Succinate - Diflucan 100 mgCialis soft tabs 40 mg You should not stop using Metoprolol Tartrate suddenly. Stopping suddenly may make your condition worse. If you have high blood pressure, keep using Metoprolol Tartrate Tartrate even if you feel well. High blood pressure often has no symptoms. You may need to use Metoprolol Tartrate for the rest of your life. Metoprolol Tartrate Uses, Side Effects &. Alternatives for Metoprolol Succinate. Contraindications for Metoprolol Succinate Oral -. In addition see Indications. Angina pectoris. The daily oral dose is 100 to 200 mg, given in 2 divided doses; if necessary, the daily dose can be increased to. Medscape - Hypertension-specific dosing for Lopressor, Toprol XL, Kapspargo Sprinkle metoprolol, frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. Dec 7, 2018. Metoprolol is used to treat angina chest pain and hypertension high blood pressure. Learn about side effects, interactions and indications.